Lopinavir/Ritonavir in the Treatment of COVID-19:A Systematic Review and Meta-Analysis  

作　　者：Yan Du Tongtong Wang Bo Li Fang Pang Xuanguo Zhang Li Xi 

机构地区：[1]Jiayuguan Health Commission,Jiayuguan 735100,China [2]Infectious Diseases Department,Shaanxi Traditional Chinese Medicine Hospital,Xi'an 710003,China [3]Department of Pharmacy,Shaanxi Traditional Chinese Medicine Hospital,Xi'an 710003,China [4]College of Traditional Chinese Medicine,Chongqing Medical University,Chongqing 400016,China [5]Emergency Department and Intensive Care Unit,Shaanxi Traditional Chinese Medicine Hospital,Xi'an 710003,China [6]Editorial Department of Shaanxi Journal of Traditional Chinese Medicine,Shaanxi Academy of Traditional Chinese Medicine,Xi'an 710003,China

出　　处：《Proceedings of Anticancer Research》2021年第5期19-25,共7页抗癌研究

摘　　要：Objective:To systematically evaluate the efficacy and safety of lopinavir/ritonavir(LPV/r)in the treatment of COVID-19.Methods:PubMed,Embase,Ovid,CNKI,CBM,Wanfang,and VIP databases were searched to obtain the clinical studies of LPV/r in the treatment of COVID-19 from December 2019 to July 2020.The literatures were screened according to the inclusion and exclusion criteria.Their qualities were evaluated according to the Newcastle-Ottawa Scale(NOS)and RevMan 5.3 software was used for meta-analysis.Results:A total of 688 patients were included in five studies,involving China and France.Compared with patients in the control group,who was only treated with routine treatment,there were no significant differences of the 7-day nucleic acid negative conversion rate and 14-day nucleic acid negative conversion rate in the treatment group.However,the use of LPV/r increased the incidence of adverse reactions in the treatment group compared to the control group.Conclusion:There is no available evidence to support the use of Lopinavir/ritonavir in the treatment of COVID-19.

关 键 词：Lopinavir/ritonavir COVID-19 SARS-CoV-2 Systematic review META-ANALYSIS 

分 类 号：R73[医药卫生—肿瘤]